Background
Methods
Patients
Blood collection and sputum processing
Genotyping
Assay of human leukocyte elastase activity
Bone density assessment
Statistical analysis
Ethics approval
Results
Genotype | Healthy children | CF patients |
p
|
---|---|---|---|
TNF-α–308GG | 93 (72%) | 145 (73%) | 0.728 |
TNF-α–308GA | 33 (26%) | 53 (27%) | 0.913 |
TNF-α–308AA | 3 (2%) | Not found | 0.118 |
Allele frequency, G/A | 0.85/0.15 | 0.87/0.13 | 0.921 |
LT-α + 252GG | 13 (10%) | 12 (6%) | 0.272 |
LT-α + 252GA | 42 (33%) | 67 (36%) | 0.633 |
LT-α + 252AA | 72 (57%) | 110 (58%) | 0.854 |
Allele frequency, A/G | 0.27/0.73 | 0.24/0.76 | 0.263 |
Associations with lung diseases
TNF genes | FVC | p* | FEV1 | p* |
---|---|---|---|---|
TNF-α-308GA – LT-α + 252AA | 96.9 ± 9.5 (n = 12) | 91.5 ± 10.4 (n = 12) | ||
TNF-α-308GG – LT-α + 252AA | 78.8 ± 2.6 (n = 94) | 0.025 | 70.3 ± 2.8 (n = 94) | 0.015 |
TNF-α-308GA – LT-α + 252AG | 72.5 ± 4.2 (n = 27) | 0.008 | 66.4 ± 5.5 (n = 27) | 0.009 |
TNF-α-308GG – LT-α + 252AG | 78.1 ± 3.8 (n = 33) | 0.025 | 72.6 ± 4.6 (n = 32) | 0.027 |
TNF-α-308GG – LT-α + 252GG together with TNF-α-308GA – LT-α + 252GG | 76.1 ± 6.8 (n = 11) | 0.029 | 69.3 ± 8.9 (n = 11) | 0.039 |
Genotype | Asthma | Tuberculosis | Virus hepatitis |
---|---|---|---|
TNF-α–308 GG | 5.8% | 5.0% | 6.3% |
(n = 145) | (8/145) | (7/140) | (8/143) |
TNF-α–308GA | 14.0% | 2.9% | 3.8% |
(n = 53) | (7/53) | (2/51) | (2/53) |
P-value | 0.068 | 0.94 | 0.9 |
LT-α + 252AA | 6.5% | 8.3% | 6.4% |
(n = 110) | (7/110) | (9/108) | (7/109) |
LT-α + 252GA | 7.8% | 0% | 0% |
(n = 67) | (5/67) | (0/65) | (0/65) |
LT-α + 252GG | 10.0% | 0% | 16.7% |
(n = 12) | (1/12) | (0/11) | (1/12) |
P value | PA/A,G/A = 0.013 | PA/A,G/A = 0.035 | |
PA/A,G/G+G/A = 0.007 | PA/A,G/G+G/A = 0.088 |
Associations with CF related liver diseases
TNF genes | Cirrhosis (total) | p* | p** | Cirrhosis (without PH) | p* | p** |
---|---|---|---|---|---|---|
TNF-α-308GA–LT-α + 252AA | 1/13 (7.7%) | 0.061 | 0.018 | 0/13 | 0.028 | 0.016 |
TNF-α-308 G–LT- + 252AA | 31/97 (32%) | — | >0.1 | 25/97 (25.8%) | — | >0.1 |
TNF-α-308GA–LT- + 252AG | 13/29 (44.8%) | >0.1 | — | 9/29 (31.0%) | >0.1 | — |
TNF-α-308GG–LT- + 252AG | 5/37 (13.5%) | 0.023 | 0.005 | 4/37 (10.8%) | 0.045 | 0.041 |
TNF-α-308GG–LT- + 252GG together with | 2/12 (16.7%) | >0.1 | 0.087 | 0/12 | 0.036 | 0.029 |
TNF-α-308GA–LT- + 252GG |